SOHO 2020: Cross-Study Comparison of Carfilzomib, Dexamethasone, and Daratumumab Dosing Regimens in Myeloma
Posted: Thursday, October 8, 2020
A cross-study comparison of the CANDOR and EQUULEUS trials suggested that a once-weekly dosing regimen of carfilzomib, dexamethasone, and daratumumab (70 mg/m2) may be more convenient for patients with relapsed or refractory multiple myeloma than a lower twice-weekly dosing regimen (56 mg/m2). Xavier Leleu, MD, PhD, of the Academic Hospital of Poitiers, France, and colleagues indicated that the results may encourage greater treatment adherence and enhance quality of life, potentially leading to improved clinical outcomes. The findings were presented at the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract MM-040).
The triplet combination consisting of carfilzomib, dexamethasone, and daratumumab was assessed at two dosing regimens for patients with relapsed or refractory multiple myeloma: twice weekly at 56 mg/m2 in the CANDOR trial and once weekly at 70 mg/m2 in the MMY1001/EQUULEUS trial. To mitigate potential confounding factors that may have influenced efficacy, propensity score matching was used to derive a weighted patient group from the CANDOR study (n = 89.3 of 185) that was similar to the EQUULEUS (n = 85) group. It was not a whole number because it represented a weighted sum of patients rather than “matched” patients.
The overall response rate and progression-free survival results were consistent for both groups before and after propensity score adjustment. The safety profiles were also comparable between the two studies. Serious adverse events were reported in 58.9% of patients in the CANDOR study and 48.2% of patients in the EQUULEUS study. Fatal adverse events occurred in both cases (10.8% vs. 3.5%, respectively). The median duration of carfilzomib treatment was longer for the once-weekly regimen (66 weeks) than the twice-weekly regimen (54.3 weeks), indicating patients may remain on the 70 mg/m2 treatment longer to achieve optimal response and survival benefits.
Disclosure: No disclosure information was provided for the study authors.
